FDA Drafts Rules to Detect Chemicals Leaching into Drugs
Published Date: 12/1/2025
Notice
Summary
The FDA just released a draft guide to help drug makers check for tiny chemicals that might sneak out of packaging or ingredients and into medicines. This new plan affects pharmaceutical companies by giving them clear, risk-based steps to keep medicines safe and high-quality. Comments are open until January 30, 2026, so companies should act fast to share their thoughts and prepare for possible changes that could impact costs and processes.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
ICH Q3E Draft Gives Global Framework
The FDA published a draft ICH Q3E guidance on December 1, 2025 that gives drug makers a holistic, risk-based framework to assess and control extractables and leachables to help ensure patient safety and product quality. The ICH Assembly endorsed the draft in August 2025 and FDA is making it available for public comment as it works toward a final guidance.
New E&L Thresholds and Monographs
The draft guidance discusses thresholds for identifying, quantifying, and reporting extractables and leachables (E&L) and includes draft Class 3 leachable monographs in its supporting documentation. Drug makers will need to review these thresholds and monographs and may need to change testing, reporting, or quality-control processes accordingly.
Public Comment Deadline — Act Now
FDA requests comments on the draft Q3E guidance; comments must be submitted by January 30, 2026 for consideration before work on the final guidance. Companies that want to influence the final text or raise cost concerns should submit comments by that date.
Draft Guidance Is Non-Binding, Final Will Consider Costs
The notice states FDA guidance documents are not legally enforceable and describe the Agency's current thinking; alternative approaches that satisfy statutes/regulations remain permitted. FDA also said it will consider comments on costs or cost savings (relevant to Executive Order 14192) as it develops the final guidance.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2025-21701 — Combined Notice of Filings
The Federal Energy Regulatory Commission got new filings about natural gas pipeline rates and refunds from companies like Midcontinent Express and Young Gas Storage. These filings could change how much customers pay starting December 1, 2025, and January 1, 2026. If you want to speak up or get involved, you have until December 8, 2025, to file your comments or protests.
Next: 2025-21703 — Agency Information Collection Activity: Notice of Disagreement: Appeal to the Board of Veterans' Appeals
The Department of Veterans Affairs is updating the forms veterans use to appeal decisions about their benefits. Veterans who disagree with a VA decision will still use these forms, but the VA wants your feedback on making the process easier and clearer. Comments are open until January 30, 2026, and this update won’t cost veterans extra money or add delays.